Members of the Innovative Pharmaceutical Initiative (iF!) recorded at least HRK 113.6 million* in transferred value in 2016 to healthcare organisations and healthcare professionals Of this, around HRK 48.7 million, or 42.9 percent, relates to healthcare professionals, while at least HRK 36.8 million, or 32.4 percent of the total transferred value, was transferred to healthcare organisations. Last year, the innovative pharmaceutical industry in Croatia invested HRK 28 million in research and development. This is 14 percent more than in 2015 and confirms the recognition of Croatian physicians and healthcare institutions for their standards in new‑medicine research. and confirms the recognition of Croatian physicians and healthcare institutions for their standards in new‑medicine research.

Twenty‑three innovative pharmaceutical companies operating in Croatia publicly disclosed, by 30 June, data on transfers of value to physicians and healthcare organisations made during 2016, which since the previous year has been standard practice for the innovative pharmaceutical industry in 33 countries.

In line with Croatian laws that guarantee the protection of personal data, 11 percent of physicians voluntarily provided their data for individual publication of value‑transfer information.

With the aforementioned funds, the innovative pharmaceutical industry has, for example, through sponsorships and donations, enabled the implementation of projects by healthcare organisations. In addition to the professional development of physicians, cooperation between industry and healthcare professionals also includes participation in medical and educational meetings, where physicians provide their expertise, time, and work, for which they receive fair compensation. Research and development refer to the processes of collecting data on the efficacy and safety of specific medicines or medical procedures, and are conducted through clinical studies and collaboration with healthcare organizations, healthcare professionals, and patients. Beyond the value transfers themselves, R&D processes bring additional value through free medicines and the education of physicians in new treatment methods.